First-year experiences with the Interagency Guidelines for Drug Donations (WHO/EDM, 2000, 51 p.): References

First-year experiences with the Interagency Guidelines for Drug Donations (WHO/EDM, 2000, 51 p.)

		(introductory text...)
		Acknowledgements
		Executive summary
		1. Introduction
		2. Sources of information and study methodology
		3. Dissemination and uptake of the Guidelines
		4. Basic characteristics of drug donations
		5. Practical benefits as a result of the Guidelines
		6. Drug donations which were hampered, delayed or cancelled
		7. Experiences and opinions regarding the 12-month shelf-life requirement
		8. Other suggestions to improve the Guidelines
		9. How could donation practice be further improved?
		10. Summary of recommendations
		11. Postscript
		References

References

1. Autier P et al. Drug supply in the aftermath of the 1988 Armenian earthquake. Lancet 1990; i:1388–1390.

2. Forte GB et al. An ounce of prevention is worth a pound of cure. Presentation at the International Conference of Drug Regulatory Agencies, The Hague, 1994.

3. MSH/WHO/DAP. Managing drug supply. 2nd edition. Hartford, CT: Kumarian Press, 1997. Management Sciences for Health in collaboration with World Health Organization, Action Programme on Essential Drugs. Edited by Quick JD, Rankin J, Laing RO, O’Connor R, Hogerzeil HV, Dukes MNG, and Garnet A.

4. Reich MR, editor. An assessment of US pharmaceutical donations: players, processes and products. Boston: Harvard School of Public Health, 1999.